Zoetis price target lowered to $225 from $230 at HSBC

HSBC analyst Sidharth Sahoo lowered the firm’s price target on Zoetis to $225 from $230 and keeps a Buy rating on the shares. While the competitor product launches remain in focus, HSBC sees an attractive risk/reward given the recent pullback in the shares, the analyst tells investors in a research note. The firm says Simparica Trio, osteoarthritis pain products, and pricing in hyperinflationary markets drove solid operational growth for Zoetis in Q1.